Spire Wealth Management Sells 4,235 Shares of Cencora, Inc. $COR

Spire Wealth Management cut its stake in shares of Cencora, Inc. (NYSE:COR) by 70.3% in the third quarter, HoldingsChannel reports. The fund owned 1,789 shares of the company’s stock after selling 4,235 shares during the period. Spire Wealth Management’s holdings in Cencora were worth $559,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC boosted its position in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares during the period. Vermillion & White Wealth Management Group LLC boosted its holdings in Cencora by 69.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after buying an additional 43 shares during the period. Caldwell Trust Co purchased a new stake in Cencora in the 2nd quarter worth $46,000. Salomon & Ludwin LLC raised its holdings in Cencora by 638.1% during the third quarter. Salomon & Ludwin LLC now owns 155 shares of the company’s stock valued at $47,000 after acquiring an additional 134 shares during the period. Finally, Capital A Wealth Management LLC lifted its position in shares of Cencora by 3,975.0% in the second quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock valued at $49,000 after acquiring an additional 159 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the subject of several research analyst reports. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. TD Cowen boosted their target price on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Robert W. Baird set a $392.00 target price on shares of Cencora in a research report on Tuesday, December 16th. Finally, Barclays started coverage on shares of Cencora in a report on Monday, December 8th. They issued an “overweight” rating and a $400.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $379.50.

Insider Buying and Selling

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the sale, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at $12,398,792. This represents a 11.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 20,317 shares of company stock valued at $7,009,260. Company insiders own 10.80% of the company’s stock.

Cencora Stock Down 0.0%

Shares of NYSE:COR opened at $335.73 on Friday. The company has a 50-day moving average price of $349.89 and a 200 day moving average price of $318.27. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a 12 month low of $233.61 and a 12 month high of $377.54. The company has a market cap of $65.13 billion, a price-to-earnings ratio of 42.23, a PEG ratio of 1.60 and a beta of 0.66.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same quarter in the previous year, the business earned $3.34 EPS. The company’s quarterly revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were issued a $0.60 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is 30.19%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.